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appropriate in the setting of Delayed
stereotactic radiosurgery for Brain 
Metastases?
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Objectives: To determine if five commonly used prognostic indices (PIs) – recursive 
partitioning analysis (RPA), Score Index for Radiosurgery (SIR), Basic Score for Brain 
Metastases (BSBM), graded prognostic assessment (GPA), and the diagnosis-specific 
GPA – are valid following delay between diagnosis and treatment of brain metastases.
Methods: In a single-institutional cohort, records of patients who underwent ste-
reotactic radiosurgery (SRS) more than 30  days from diagnosis of brain metastases 
were collected, and five PI scores were calculated for each patient. For each PI, three 
score-based groupings were made to examine survival differences by means of adjusted 
log-rank analysis and area under the curve (AUC).
results: Of 121 patients with sufficient PI information, 72 underwent SRS more than 
30 days after diagnosis. Median age and Karnofsky performance status were 60 years 
and 80, respectively. Forty-three (60%) patients had lung primaries. Prior to SRS, 38 
(52.8%) and 12 (16.7%) patients underwent whole brain radiation therapy (WBRT) and 
surgery, respectively. Two (2.8%) patients underwent both WBRT and surgery prior to 
SRS. A median of two lesions were treated per SRS course. Median survival of the 
cohort was 9.0  months. Using adjusted log-rank analysis for pairwise comparison, 
BSBM and GPA showed significance between two out of the three prognostic groups, 
while the other scores showed either one or no significant differences on comparison. 
AUC demonstrated good applicability for BSBM, RPA, and GPA, although SIR was 
statistically less prognostic than the other PIs.
conclusion: The PIs analyzed in this study were applicable in the setting of delayed 
SRS. Although these data are hypothesis generating, they serve to encourage further 
analyses to validate a PI that is most optimal for these patients.
Keywords: brain metastases, brain tumor, prognosis, radiation therapy, stereotactic radiosurgery
inTrODUcTiOn
Accounting for over half of brain tumors, brain metastases are estimated to arise in 25–35% of all 
cancer patients (1, 2). Moreover, the incidence of metastatic brain disease has increased with more 
sensitive intracranial imaging and improved survival of patients with metastatic cancer as compared 
to the past (3–5). In the modern era, oncologic treatment for brain metastases includes whole brain 
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radiation therapy (WBRT), surgical resection, stereotactic radio-
surgery (SRS), systemic targeted therapy, or combinations of the 
aforementioned.
It is important, however, to appreciate those patients with brain 
metastases are undoubtedly part of a heterogeneous population, 
thus having direct implications on treatment paradigms. In order 
to better stratify patients based on expected prognosis, several 
numerical scoring systems have been proposed. These prognostic 
indices (PIs) may aid clinicians in selecting patients with longer 
expected survival who may potentially experience late effects of 
WBRT and hence benefit from SRS (6–10).
The Radiation Therapy Oncology Group (RTOG) recursive 
partitioning analysis (RPA) used data from three randomized 
trials (11–13) and was designed to explain differences in 
survival by dividing patients into prognostic subgroups (6). 
Several important variables were utilized in scoring, includ-
ing but not limited to Karnofsky performance status (KPS), 
primary tumor control, age, and extracranial metastases. Next, 
the Score Index for Radiosurgery (SIR) was designed specifi-
cally for patients who undergo radiosurgery (7). In contrast to 
the RPA grouping, the SIR is a numerical scale applied to the 
sum of 5 prognostic factors, each having a category rated from 
0 to 2. Although similar to the RPA (age, KPS, and extracranial 
disease), SIR also incorporates the number of metastases and 
the volume of the largest lesion. The Basic Score for Brain 
Metastases (BSBM) was derived by Lorenzoni et  al. from a 
cohort of patients who underwent Gamma Knife radiosurgery 
(8). Though it largely does not account for tumor factors as in 
the SIR, it provides the most simplified analytic framework. 
This involves examining three categories (KPS, primary tumor 
control, and extracranial metastases) while using a numerical 
system in which total scores range from 0 to 3. Subsequently, 
the graded prognostic assessment (GPA) was a modification 
of the RPA based on data from the RTOG9508 trial, which 
demonstrated number of metastases to be prognostic (14, 15). 
In doing so, parameters such as systemic disease control (rela-
tively subjective) and tumor volume (liable to change based on 
prior treatment) were removed. As a result, this PI includes 
age, KPS, number of intracranial metastases, and presence of 
extracranial metastases. Finally, owing to the heterogeneity 
of patients with similar GPA scores, a diagnosis-specific GPA 
(DSGPA) was formulated by examining individual tumor types 
as an independent prognostic factor (16). By subcategorizing 
patients by primary tumor, the DSGPA offered greater prognos-
tic value for tumors such as melanoma, renal cell carcinoma, 
and gastrointestinal primaries.
Amidst the strong prognostic impact of these PIs, several short-
comings should be noted. Many of these PIs predate advances in 
screening and treatment for both intracranial and extracranial 
disease (17). Moreover, the recent rise of systemic and biologic 
therapy for metastatic cancer may affect measurement of various 
parameters and potentially alter accuracy of various PIs. Because 
the indices were validated to estimate survival specifically at the 
time of initial brain metastatic diagnosis, their prognostic value 
at certain time points after the initial diagnosis remains unclear. 
This is an important issue to address; the recent advent of several 
options to manage brain metastases often results in a delay in 
SRS as compared to prior studies. To date, there have been no 
publications examining PIs in patients undergoing delayed SRS. 
Therefore, in this study, we compared each of the five PIs (such 
as RPA, SIR, BSBM, GPA, and DSGPA) in an institutional cohort 
with brain metastases treated with SRS at least 30 days after being 
diagnosed with brain metastasis. In doing so, we aimed to exam-
ine which PIs were most appropriate for the growing number of 
patients who undergo delayed SRS (e.g., due to logistics, surgery, 
WBRT, systemic therapy, personal preferences, etc.).
MaTerials anD MeThODs
This study, approved by the Institutional Review Board, retro-
spectively reviewed all patients who completed a course of SRS 
between 2009 and 2014. Analyzed patients were those who had 
an interval of over 30  days between initial diagnosis of brain 
metastases and SRS treatment. This threshold was used in order 
to provide a “meaningfully delayed” time point which encom-
passed a sufficient sample size of patients. Data collected for 
each patient included specifics related to each particular patient, 
primary disease, metastatic brain disease, and treatment factors 
both prior to and after SRS. Patient factors included age, gender, 
symptoms and performance status. Disease factors included 
date of primary diagnosis, date diagnosed with brain metas-
tases, primary site, histology, subtype if applicable, number of 
lesions, control of systemic disease, and presence of extracranial 
metastases. Treatment factors detailed use of corticosteroids, any 
previous treatments, and specifics of SRS delivery. Response to 
SRS was noted, as well as the date of last radiologic and clinical 
follow-up (including death).
Using these variables, RPA, SIR, BSBM, GPA, and DSGPA 
were calculated for each patient. For each PI, excluding DSGPA, 
patients were then organized into three groups based on score; 
numerical score cutoffs separating these groups was logically 
performed to ensure relatively uniform sample sizes in each 
group. Groupings were also based on similar expected survival 
based on prior publications, in efforts to decrease heterogeneity 
between grouped populations. For RPA scores, groups were made 
according to each numerical score (1, 2, and 3). Regarding SIR, 
scores of 1–3 were categorized as group 1, 4–6 were as group 2, 
and 7–9 as group 3. Similarly, a BSBM score of 0 was classified 
as group 1, a score of 1 corresponded with group 2, and scores 
of 2–3 were denoted as group 3. Regarding GPA, scores 0–1 
were assigned to group 1, 1.5–2.5 to group 2, and 3–4 to group 
3. DSGPA was calculated using the diagnostic information of 
the primary tumor from the following categories: non-small cell 
lung cancer (NSCLC), melanoma, breast, renal cell carcinoma, or 
gastrointestinal tumors. For the analysis of time from diagnosis 
to treatment as a prognostic factor, groupings were as follows: 
30–44, 45–59, 60–89, and >90 days.
Kaplan–Meier survival curves for each group were then 
compiled for each PI. Survival was determined from the date of 
SRS to the date of last contact or death. Statistical analysis was 
performed using the SAS software, version 9.4 (SAS Institute 
Inc., Cary, NC, USA). Pairwise comparison of the groups was 
then preformed using the log-rank test and was adjusted for 
multiple comparisons. The Tarone–Ware test was used to account 
TaBle 1 | clinical and treatment characteristics of the study population.
Parameter Value
Median (range) age, years 60 (25–90)
gender
Male 0.42 (58.3%)
Female 30 (41.7%)
ecOg performance status
0 0.8 (11.1%)
1 39 (54.2%)
2 15 (20.8%)
3 9 (12.5%)
4 1 (1.4%)
Karnofsky performance status
30 0.1 (1.4%)
40 0 (0.0%)
50 9 (12.5%)
60 5 (6.9%)
70 9 (12.5%)
80 20 (27.8%)
90 21 (29.2%)
100 7 (9.7%)
symptoms at presentation
Asymptomatic 0.12 (16.7%)
Headache 10 (13.9%)
Visual 9 (12.5%)
Parameter Value
Sensorimotor 6 (8.3%)
Mental status 4 (5.6%)
Nausea 3 (4.2%)
Balance 3 (4.2%)
Seizure 2 (2.8%)
Other 6 (8.3%)
Unknown 17 (23.6%)
Primary site
Lung 0.43 (59.7%)
Melanoma 9 (12.5%)
Breast 8 (11.1%)
Kidney 5 (6.9%)
Gastrointestinal 3 (4.2%)
Genitourinary 2 (2.8%)
Other 2 (2.8%)
receipt of surgery
For any other lesion(s) 0.19 (26.4%)
For lesion treated with SRS 12 (16.7%)
receipt of WBrT 40 (55.6%)
30 Gy in 10 fractions 15 (20.8%)
37.5 Gy in 15 fractions 15 (20.8%)
Other 10 (25.0%)
Previous srs
For any other lesion(s) 0.4 (5.6%)
For lesion treated with SRS 0 (0.0%)
control of primary tumor
Yes 0.34 (47.2%)
No 38 (52.8%)
systemic disease status at treatment
Progressive 0.32 (44.4%)
Stable 29 (40.3%)
None 11 (15.3%)
Presence of extracranial metastases
Yes 0.36 (50.0%)
No 36 (50.0%)
reason for delayed srs
WBRT 0.38 (52.8%)
Surgery 12 (16.7%)
WBRT and surgery 2 (2.8%)
Targeted therapy 1 (1.4%)
Patient preference/other 19 (26.4%)
Median (range) lesions treated 2 (1–5)
Median (range) SRS dose (Gy) 18 (13–24)
Median (range) GTV volume (cc) 1.1 (0.03–15.2)
Median (range) PTV volume (cc) 1.9 (0.05–17.8)
Median (range) margin from GTV to PTV (mm) 1.0 (0.0–2.0)
immobilization technique
Frame-based 0.22 (30.6%)
Frameless 50 (69.4%)
response after srsa
Complete response 0.11 (15.3%)
Partial response 9 (12.5%)
Stable disease 28 (38.9%)
Progressive disease 12 (16.7%)
Unknown 12 (16.7%)
ECOG, Eastern Cooperative Oncology Group; SRS, stereotactic radiosurgery; 
WBRT, whole brain radiation therapy; GTV, gross tumor volume; PTV, planning target 
volume.
aResponse after SRS was determined using the RECIST criteria for tumor response (18).(Continued)
TaBle 1 | continued
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for non-proportionality. The area under the receiver operator 
characteristic curve was calculated for each index. Statistical 
significance was established using a p-value of <0.05.
resUlTs
Of the 121 patients who had sufficient information necessary 
for the calculation of the studied PIs (such as RPA, SIR, BSBM, 
GPA, and DSGPA), 72 patients had undergone SRS more than 
30 days following initial diagnosis of brain metastases. Table 1 
illustrates clinical and treatment characteristics of these patients. 
The median age and KPS at time of SRS were 60 (range 25–90) 
years and 80 (range 50–100), respectively. The median time from 
diagnosis to SRS was 2.9 (range 1–82) months. A median of 2 
(range 1–5) tumors were treated per SRS course, at a median dose 
of 18 (range 13–24) Gy. The median interval between SRS and 
last follow-up, either by death or last clinical follow-up, was 6.7 
(range 0.2–35.6) months. The median survival was 9.0 months, 
with 6- and 12-month survival rates of 64 and 31%, respectively. 
When all group 1s, 2s, and 3s for all PIs were analyzed together, 
unadjusted pairwise comparison showed significant differences 
in survival between groups 1 and 2 (p = 0.002), groups 1 and 3 
(p < 0.001), and groups 2 and 3 (p = 0.045).
Regarding RPA, 15 patients were given a score of 1, 41 patients 
scored 2, and 16 patients scored 3. Based on the SIR index, 12 patients 
were assigned to group 1, 45 patients in group 2, and 15 patients in 
group 3. For BSBM, groups 1, 2, and 3 consisted of 9, 24, and 39 
patients, respectively. In the analysis of GPA, group 1 consisted of 15 
patients, group 2 had 42 patients, and group 3 included 15 patients.
FigUre 1 | Kaplan–Meier survival curves, grouped by sir (a), rPa (B), BsBM (c), gPa (D), and DsgPa (e).
4
Malouff et al. Prognostic Indices in Delayed SRS
Frontiers in Oncology | www.frontiersin.org November 2016 | Volume 6 | Article 248
Adjusted pairwise comparison of the prognostic groupings in 
SIR found no statistical difference between any group (Figure 1A; 
Table 2). Although one comparison was statistically significant 
for RPA, the other two failed to be significant (Figure  1B). In 
contrast, two of the three comparisons were significant in BSBM 
and GPA, while the third was not significant (Figures 1C,D).
For DSGPA, 43 patients were in group 1 (NSCLC), 9 patients 
were in group 2 (melanoma), 8 patients were in group 3 (breast 
TaBle 2 | survival and comparison between groups based on each prognostic index.
index Median survival in months (95% ci) p-Values of comparative survival
group 1 group 2 group 3 group 1 vs. 2 group 1 vs. 3 group 2 vs. 3
RPA 4.7 (1.6 to 6.2) 9.4 (6.8 to 12.4) 10.5 (9.2 to –) 0.13 <0.01 0.88
SIR 4.7 (0.7 to 8.5) 9.3 (6.8 to 10.5) 12.3 (4.8 to –) 0.38 0.09 0.99
BSBM 3.0 (0.7 to 7.6) 5.8 (3.4 to 8.7) 12.4 (9.3 to 20.6) 0.88 <0.01 <0.01
GPA 3.0 (0.7 to 6.2) 9.2 (5.9 to 12.4) 10.5 (9.3 to 20.6) 0.02 <0.01 1.00
RPA, recursive partitioning analysis; SIR, Score Index for Radiosurgery; BSBM, Basic Score for Brain Metastases, GPA, graded prognostic assessment.
FigUre 2 | area under rOc curves for sir, rPa, BsBM, and gPa.
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cancer), 5 patients were in group 4 (renal cell carcinoma), and 3 
patients were in group 5 (gastrointestinal). All comparisons by 
histologic type for DSGPA failed to reach statistical significance, 
as the adjusted log-rank p-values were >0.05 (Figure 1E).
To better approximate prognostic values, the area under the 
curve (AUC) was calculated for SIR, BSBM, GPA, and RPA. 
Similar areas under the curve were observed with RPA (0.7569), 
BSBM (0.7742), and GPA (0.7694). However, SIR had a statisti-
cally significant decreased AUC (0.6679) as compared to GPA 
when (p = 0.04; Figure 2).
Several patient factors were analyzed to determine impact 
on prognosis. Forty patients received WBRT prior to SRS, while 
32 patients did not receive previous WBRT. Those receiving 
WBRT had a worse median survival (6.16 months) compared to 
those who did not receive WBRT (10.10 months; p = 0.01). As 
expected, the 15 patients with a KPS < 70 at presentation had a 
worse median survival (4.66 months) than the 57 patients with a 
KPS of 70 or higher (9.41 months; p < 0.01). The number of brain 
metastases at presentation was found not to be prognostic, as the 
22 patients with 1 brain metastasis (8.39  months) had similar 
median survivals to the 50 patients with more extensive disease 
(8.79 months; p = 0.58).
The impact of time between diagnosis and treatment as 
a prognostic factor was then analyzed. Thirteen patients 
received treatment between 30 and 44  days after diagnosis, 
with a median survival of 5.47  months. Eleven received treat-
ment after 45–59 days, with a median survival of 5.77 months. 
Twelve patients received treatment after 60–89  days and had 
a median survival of 7.77  months, while 36 patients received 
treatment >90 days after diagnosis and had a median survival of 
9.97 months. Although there was a trend toward longer survival 
with more time between diagnosis and treatment, there was no 
statistically significant difference between groups by the log-rank 
test (p = 0.20).
DiscUssiOn
This is the first known study to examine the validity of several PIs 
(RPA, SIR, BSBM, GPA, and DSGPA) in an era of delayed SRS, 
with the increase in delays owing to more advances in treatment 
options prior to SRS. We demonstrate that all PIs show appropri-
ate prognostic capabilities, with BSBM and GPA showing greater 
prognostic validity than RPA, SIR, or DSGPA.
Despite this, a main theme of our research is that certain PIs 
can be limited in the setting of delayed SRS. Similarly, Yamamoto 
et al. have detailed the limitations of RPA and BSBM as applying 
to patients undergoing repeat SRS (19). Additionally, a caveat 
associated with RPA is that it was originally designed for use in 
WBRT, while the other indices were developed for radiosurgery 
(20). Moreover, when using high-quality data from the RTOG 
database, Sperduto et  al. demonstrated that median survivals 
often vastly differ from the original studies from which PIs were 
reported (14). For instance, the group observed median survival 
of 8.8 and 2.2 months in patients graded as SIR 8–10 and BSBM 
3; median survivals of the original studies were 31.4 months and 
not reached, respectively (7, 8, 14). Furthermore, a recent study 
by Kondziolka and colleagues revealed that up to 45% of PI-based 
predictions differed by over 6 months (21). Furthermore, DSGPA 
can only be applied to the six subtypes of primary tumors, limit-
ing its use for brain metastases arising from less common sites 
(19). Taken together, the specific patient population is integral to 
the applicability and prognostic impact of each PI.
Table  3 shows a comparison of our data with results from 
the original reports of each PI, recognizing that differing patient 
TaBle 3 | comparison of median survivals between this study and original studies for each parameter.
index Median survival (months), group 1 Median survival (months), group 2 Median survival (months), group 3
current study Original study current study Original study current study Original study
RPA 4.7 2.3 9.4 4.2 10.5 7.1
SIRa 4.7 2.9 9.3 7.0 12.3 31.4
BSBMb 3.0 1.9 5.8 3.3 12.4 13.1+
GPAc 3.0 2.6 9.2 3.8 10.5 6.9–11.0
RPA, recursive partitioning analysis; SIR, Score Index for Radiosurgery; BSBM, Basic Score for Brain Metastases, GPA, graded prognostic assessment.
aOriginal study grouped SIR by 1–3, 4–7, and 8–10 (current study with 1–3, 4–6, and 7–9).
bOriginal study grouped BSBM by 0, 1, 2, and 3 (current study 0, 1, and 2–3).
cOriginal study grouped GPA by 0–1, 1.5–2.5, 3, and 3.5–4 (current study 0–1, 1.5–2.5, and 3–4).
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populations and grouping schemes make this comparison inher-
ently faulty. In the worst prognostic group (group 1), GPA pre-
dicted survival most closely, and RPA the least. However, in group 
2, GPA provided the greatest underestimation, while SIR was the 
numerically closest parameter. Group 3 has, as mentioned, been 
most liable to misestimations, but both GPA and BSBM provided 
close estimations in our patient population. Notably, other stud-
ies’ expected survivals underestimated those for both groups 1 
and 2, likely a reflection of improved pre-SRS diagnosis and treat-
ment. Collectively, this rough comparison further concludes that 
different PIs may be differentially accurate in various groups of 
patients, a notion that is not uncommon among other oncological 
prognostic tools.
One of the major limitations of using PIs in any situation is 
the lack of consideration for genetic differences in tumors. For 
example, lapatinib has been found to affect survival of patients 
with brain metastases from HER2-positive breast cancers (22, 
23). As such, one study developed and validated a nomogram 
for survival in breast cancer that factored in number of CNS 
metastases, size of largest brain metastasis, and biomarker status 
(24). Further research could adapt the nomograms to include 
a component for differences in survival from time of diagnosis 
to radiotherapeutic treatment, which could provide a more per-
sonalized prognostic timeline for patients considering a delay in 
receiving SRS.
While our study consisted of five of the most widely used 
prognostic scoring systems, there are other systems that may 
have value in the delayed setting. The Rotterdam score, which 
builds upon other PIs by including response to corticosteroids, 
systemic tumor activity, and serum lactate dehydrogenase, was 
validated in 1999 (25). However, the utilization of the Rotterdam 
score is less prevalent, owing to a dearth of consistent or suf-
ficient data examining corticosteroid response (22). The Golden 
Grading System (GGS) was recently proposed using age, KPS 
score, and known extracranial metastases (26). Designed for SRS, 
surgery, and WBRT, the GGS does not take into consideration 
the number of brain metastases or the primary tumor site (20). 
In 2010, Rades et  al. developed the RADES prognostic index, 
which factored in time of diagnosis from malignant disease to 
radiotherapy (27). Though this PI is potentially useful in the set-
ting of delayed SRS, the index does not account for the difference 
between diagnosing brain metastases and diagnosing primary 
malignant disease, as brain metastases often occur months after 
the diagnosis of primary malignant disease. Furthermore, the 
interval between diagnosis and treatment of primary malignant 
disease was 6 months in the report, which is significantly longer 
than expected between diagnosis of brain metastases and SRS of 
brain metastases.
There are several limitations of this study worth mentioning. 
In addition to the retrospective nature of this work, its sample 
size may not result in optimal applicability. With only 72 patients 
in our study, our data may be underpowered to pick up differ-
ences between our prognostic groupings. Additionally, analysis 
of each individual prognostic score was underpowered, with 
only a few patients in each score. Although previous WBRT 
and poor performance status at presentation were found to 
have prognostic value, their analysis was limited due to small 
sample sizes in each subgroup. Furthermore, our definition of 
delayed was determined to be more than 30 days from diagnosis, 
based on the authors’ experiences. Being a single-institutional 
study, our study was underpowered to determine differences in 
more delayed settings (i.e., more than 60 days from diagnosis). 
Moreover, though all patients received SRS, which represents a 
more aggressive treatment course, it is important to note that 
we were unable to quantify the aggressiveness used in a systemic 
approach. Another potential area for bias is the grouping of 
our PI scores. Our grouping was largely based on sample size 
considerations, and though were similar to those used in the 
original publications, could result in non-trivial differences 
in accuracy. However, patterns of grouping are a bias present 
in any retrospective data, including the original publications. 
Direct comparison of DSGPA with other PIs was impractical, 
as the prognostic value of the DSGPA varies by disease site. For 
instance, a prognostic score of 3 in brain metastases from breast 
cancer is likely to have a different survival than a prognostic 
score of 3 in NSCLC. Finally, because PI scoring is designed to 
categorize a set of intrinsically heterogeneous patients, a very 
precise estimation of survival will continue to be an elusive 
target. The grouping of “patients undergoing delayed SRS” is 
no less heterogeneous, especially in light of various reasons for 
delaying SRS.
Future directions could examine endpoints for PIs in lieu of 
survival (22). While survival is an obvious and readily determi-
nable endpoint, clinically relevant endpoints such as elsewhere 
brain failure and KPS decline may provide more relevant and 
precise information to patients. Furthermore, research could be 
performed to expand on the differences in survival among factors 
uniquely affecting patients with delayed SRS, which is becoming 
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more common as newer therapies come to the forefront of onco-
logic management.
cOnclUsiOn
As compared to the past, owing to improved diagnosis and treat-
ment of brain metastases, delay between diagnosis and SRS is a 
relatively common scenario. PIs remain useful and accurate tools 
in the setting of delayed SRS, with some limitations. Therefore, 
careful selection of PIs is warranted. Though these results are 
hypothesis-generating, validation of PIs for delayed SRS using 
prospectively collected data is highly encouraged.
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